17-AAG exerts its anti-tumor potency through its high affinity binding to the NH2-terminal ATP-interacting domain of Hsp90, thus inhibiting its ability to form transient, active homodimers, and to consequently participate in chaperone-client complexes, with a subsequent hindering of client maturation and stabilization. The gene discussed is HSP90AA1; the disease is neoplasm.